Skip to main content
Indian stocks: Visit www.stage2stocks.com →

CONMED Corporation

Stage 2 · Advancing · week 10

As of Oct 22, 2026, CONMED is in Stage 2, the uptrend phase, now in week 10 (since Aug 14, 2026). It closed at $49.44, 4.7% below its 52-week high and above its 200-day average, which is rising.

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. More about the company

$49.44
+4.95% today
$1.5B · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is CNMD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 31w
S4 21w
S4 31w
S4 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 7w → S4 9w → S1 9w → S4 31w → S1 5w → S4 9w → S1 2w → S2 5w → S3 1w → S4 21w → S1 1w → S4 31w → S1 4w → S4 17w → S1 3w → S2 10w current
Total tracked: 166 weeks across 16 stage runs.

CNMD among Medical Devices45th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…45CNMDStage 2 · wk 1056+7.9%
vs 52W High
-4.7%
$32.11 lo$51.86 hi
4.7% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 10
1w13w26w
Week 10, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
19.7%
200 DMA: $41.29 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.14x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
→
Short-term trend flat
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+7.9%
3M
+15.8%
6M
+31.8%
YTD
+22.0%
1Y
+2.2%
Scan Membership
Breakout Watch
Latest: 2025-01-03
8 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 10 · Vol 1.14x
2026-10-21S2
Wk 10 · Vol 1.24x
2026-10-20S2
Wk 10 · Vol 1.28x
2026-10-19S2
Wk 10 · Vol 0.99x
2026-10-16S2
Wk 9 · Vol 1.19x
2026-10-15S2
Wk 9 · Vol 1.15x
2026-10-14S2
Wk 9 · Vol 1.11x
2026-10-13S2
Wk 9 · Vol 1.42x
2026-10-12S2
Wk 9 · Vol 1.40x
2026-10-09S2
Wk 8 · Vol 1.06x
2026-10-08S2
Wk 8 · Vol 1.24x
2026-10-07S2
Wk 8 · Vol 1.34x
Moving averages & range
50 DMA
$47.51
200 DMA
$41.29
52W High
$51.86
52W Low
$32.11
5D Low
$46.05
Resistance levels (recent highs)
20d High
$49.44
60d High
$51.86
120d High
$51.86
250d High
$51.86
Next resistance
+4.9%
to 60d High
P/E (TTM)
26.7
Forward 10.3
Earnings Growth (YoY)
+11.2%
Revenue +0.3%
ROE
+5.5%
Profit margin +4.1%
Dividend Yield
0.00%
P/B 1.4

CONMED: quick answers

What stage is CONMED in?

As of Oct 22, 2026, CONMED (CNMD) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 14, 2026 and is in week 10. What the four stages mean

Is CONMED in an uptrend?

Yes. CONMED is in a Stage 2 uptrend. It trades 19.7% above its 200-day average, which is rising.

How far is CONMED from its 52-week high?

CONMED closed at $49.44 on Oct 22, 2026, 4.7% below its 52-week high of $51.86. Its 52-week low is $32.11.

How has CONMED performed over the past year?

As of Oct 22, 2026, CONMED is up 2.2% over the past year and up 22.0% so far in 2026.

Which sector and industry is CONMED in?

CONMED is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solutions comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures; and products to treat diseases of dilation, hemostasis, biliary, stricture management, and infection prevention, as well as ECG electrodes, EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.